Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Erivedge Efficacy Overcomes Limitations Of Single-Arm Study

Nov 01 2012

• By Sue Sutter

Related Content

Accelerated And Accompanied: Oncology Drugs Should Use Randomized Trials, FDA Panel Says

Feb 08 2011

Oncology NDAs Based On Single-Arm Studies Run Risk Of FDA Refusal To File

May 01 2011

<em>Erivedge</em> Development Timeline

Nov 01 2012

To REMS Or Not To REMS? <em>Erivedge </em>Shows Division At FDA Over Oncology Risk Management

Nov 01 2012

Related Companies

Genentech, Inc.

Eisai Co., Ltd.

Bristol Myers Squibb Company

Additional Topics

United States Drug Approval Standards BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window